Abstract
Platelets play a critical role in the pathogenesis of atherothrombotic processes and inhibition of platelet aggregation by antiplatelet therapy is essential and really important in the acute coronary syndromes or in the setting of percutaneous coronary intervention. The first family of adenosine diphosphate P2Y12 receptors inhibiting drug is represented by thienopyridines and among these ticlopidine was the first approved by Food and Drug Administration; actually its use is discouraged because of its potential side effects (neutropenia, anemia, gastrointestinal distress and thrombotic thrombocytopenic purpura). The second generation of thienopyridines is represented by clopidogrel that has replaced ticlopidine in the clinical practice; clopidogrel has the largest clinical experience. Prasugrel represents the third generation. It inhibits platelet aggregation by irreversibly blocking the adenosine diphosphate P2Y12 receptor. Ticagrelor, Cangrelor and Enilogrel represent the last generation of thienopyridines.
This review is focused on the effects of adenosine diphosphate P2Y12 inhibitors.
Keywords: Antithrombotic therapy, coronary thrombosis, acute coronary syndrome, primary PCI, coronary intervention, STEMI, P2Y12 inhibitors, pharmacologic mechanism, bleeding, in stent restenosis.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:P2Y12 Inhibitors: Pharmacologic Mechanism and Clinical Relevance
Volume: 11 Issue: 2
Author(s): Gioel Gabrio Secco, Rosario Parisi, Francesca Mirabella, Rossella Fattori, Giulia Genoni, Pierfrancesco Agostoni, Giuseppe De Luca, Paolo Nicola Marino, Alessandro Lupi and Andrea Rognoni
Affiliation:
Keywords: Antithrombotic therapy, coronary thrombosis, acute coronary syndrome, primary PCI, coronary intervention, STEMI, P2Y12 inhibitors, pharmacologic mechanism, bleeding, in stent restenosis.
Abstract: Platelets play a critical role in the pathogenesis of atherothrombotic processes and inhibition of platelet aggregation by antiplatelet therapy is essential and really important in the acute coronary syndromes or in the setting of percutaneous coronary intervention. The first family of adenosine diphosphate P2Y12 receptors inhibiting drug is represented by thienopyridines and among these ticlopidine was the first approved by Food and Drug Administration; actually its use is discouraged because of its potential side effects (neutropenia, anemia, gastrointestinal distress and thrombotic thrombocytopenic purpura). The second generation of thienopyridines is represented by clopidogrel that has replaced ticlopidine in the clinical practice; clopidogrel has the largest clinical experience. Prasugrel represents the third generation. It inhibits platelet aggregation by irreversibly blocking the adenosine diphosphate P2Y12 receptor. Ticagrelor, Cangrelor and Enilogrel represent the last generation of thienopyridines.
This review is focused on the effects of adenosine diphosphate P2Y12 inhibitors.
Export Options
About this article
Cite this article as:
Secco Gioel Gabrio, Parisi Rosario, Mirabella Francesca, Fattori Rossella, Genoni Giulia, Agostoni Pierfrancesco, Luca Giuseppe De, Marino Paolo Nicola, Lupi Alessandro and Rognoni Andrea, P2Y12 Inhibitors: Pharmacologic Mechanism and Clinical Relevance, Cardiovascular & Hematological Agents in Medicinal Chemistry 2013; 11 (2) . https://dx.doi.org/10.2174/1871525711311020005
DOI https://dx.doi.org/10.2174/1871525711311020005 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Detection of Myocardial Ischemia in Patients with Blunted Hemodynamic Response to Adenosine Stress
Current Medical Imaging The Role of Ultrasonography of Peripheral Entheses in the Diagnosis and Assessment of Spondyloarthropathies
Current Rheumatology Reviews Actions of Rho-Kinase Inhibitors in Cardiovascular Diseases
Current Enzyme Inhibition The Role of Chest High Resolution CT and RT-PCR in Diagnosis of Different Stages of Coronavirus (COVID-19) Pneumonia
New Emirates Medical Journal Usefulness of Magnetic Resonance Imaging in Cardiac and Enovascular Intervention
Current Medical Imaging Angiotensin II Type I Receptor Blocker and Endothelial Function in Humans: Role of Nitric Oxide and Oxidative Stress
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Vasopressin in Liver Disease – Should We Turn On or Off?
Current Clinical Pharmacology Therapeutic Strategies Targeting Endothelial Function in Humans:Clinical Implications
Current Vascular Pharmacology VEGF, a Mediator of the Effect of Experience on Hippocampal Neurogenesis
Current Alzheimer Research L-Arginine Analogs – Inactive Markers or Active Agents in Atherogenesis?
Cardiovascular & Hematological Agents in Medicinal Chemistry Involvement of Orexigenic Peptides in the Mechanism of Gastric Mucosal Integrity and Healing of Chronic Gastric Ulcers
Current Pharmaceutical Design Use of Medication in Coronary Imaging by CT
Current Medical Imaging Human Papilloma Virus Vaccine Associated Uveitis
Current Drug Safety What Characterizes Endothelial Dysfunction in Preeclampsia? -The Action of NO and the Production of Prostacyclin is Reduced, While EDHF is Preserved in Omental Resistance Arteries in Preeclamptic Women
Current Women`s Health Reviews Platelet Activation in Atherogenesis Associated with Low-Grade Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) Air Pollution Exposure and Blood Pressure: An Updated Review of the Literature
Current Pharmaceutical Design Ezetimibe and Reactive Oxygen Species
Current Vascular Pharmacology Regulation of Multidrug Resistance by Pro-Inflammatory Cytokines
Current Cancer Drug Targets Non-Invasive Diagnostic Tools for Investigating Endothelial Dysfunction
Current Pharmaceutical Design Anabolic Androgenic Steroid (AAS) Related Deaths: Autoptic, Histopathological and Toxicological Findings
Current Neuropharmacology